Fred Alger Management’s Ligand Pharmaceuticals LGND Stock Holding History

Fred Alger Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Sell	3,898 -1,791	-31%	-$422K	﹤0.01%	353
2026 Q1	$1.14M	Buy	5,689 +1,927	+51%	+$381K	0.01%	349
2025 Q4	$711K	Sell	3,762 -2,106	-36%	-$405K	﹤0.01%	374
2025 Q3	$1.04M	Buy	+5,868	New	+$872K	﹤0.01%	361
2018 Q3	–	Sell	-1,603	Closed	-$207K	–	563
2018 Q2	$207K	Buy	+1,603	New	+$179K	﹤0.01%	385

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fred Alger Management's LGND Position: Q2 2026 in Review

Fred Alger Management reduced its Ligand Pharmaceuticals (LGND) stake by 31% in Q2 2026, selling an estimated $422K and leaving 3,898 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Fred Alger Management first reported a position in LGND in Q2 2018 and has held it in 5 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Fred Alger Management held 3,898 shares of Ligand Pharmaceuticals worth $1.23M as of Q2 2026.
Fred Alger Management sold 1,791 Ligand Pharmaceuticals shares in Q2 2026, an estimated $422K.
Ligand Pharmaceuticals made up ﹤0.01% of Fred Alger Management's portfolio in Q2 2026, its #353 holding.
Fred Alger Management first reported a position in Ligand Pharmaceuticals in Q2 2018 and has held it in 5 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.